{"nctId":"NCT00049517","briefTitle":"Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia","startDateStruct":{"date":"2002-12-19","type":"ACTUAL"},"conditions":["Leukemia"],"count":657,"armGroups":[{"label":"Standard Daunorubicin Then Autologous HCT","type":"EXPERIMENTAL","interventionNames":["Biological: sargramostim","Drug: busulfan","Drug: cyclophosphamide","Drug: cytarabine","Drug: Daunorubicin","Procedure: Autologous HCT"]},{"label":"High-dose Daunorubicin Then Autologous HCT","type":"EXPERIMENTAL","interventionNames":["Biological: sargramostim","Drug: busulfan","Drug: cyclophosphamide","Drug: cytarabine","Drug: Daunorubicin","Procedure: Autologous HCT"]},{"label":"Standard Daunorubicin Then GO/Autologous HCT","type":"EXPERIMENTAL","interventionNames":["Biological: sargramostim","Drug: busulfan","Drug: cyclophosphamide","Drug: cytarabine","Drug: gemtuzumab ozogamicin (GO)","Drug: Daunorubicin","Procedure: Autologous HCT"]},{"label":"High-dose Daunorubicin Then GO/Autologous HCT","type":"EXPERIMENTAL","interventionNames":["Biological: sargramostim","Drug: busulfan","Drug: cyclophosphamide","Drug: cytarabine","Drug: gemtuzumab ozogamicin (GO)","Drug: Daunorubicin","Procedure: Autologous HCT"]},{"label":"Standard Daunorubicin Then Allogeneic HCT or no Consolidation","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cytarabine","Drug: Daunorubicin","Procedure: Allogeneic HCT"]},{"label":"High-dose Daunorubicin Then Allogeneic HCT or no Consolidation","type":"EXPERIMENTAL","interventionNames":["Drug: cytarabine","Drug: Daunorubicin","Procedure: Allogeneic HCT"]}],"interventions":[{"name":"sargramostim","otherNames":["Leukine"]},{"name":"busulfan","otherNames":["Myleran"]},{"name":"cyclophosphamide","otherNames":["Endoxan","Cytoxan","Neosar","Procytox","Revimmune","cytophosphane"]},{"name":"cytarabine","otherNames":["cytosine arabinoside"]},{"name":"gemtuzumab ozogamicin (GO)","otherNames":["Mylotarg"]},{"name":"Daunorubicin","otherNames":["daunomycin","daunomycin cerubidine"]},{"name":"Autologous HCT","otherNames":["Autologous hematopoietic cell transplantation"]},{"name":"Allogeneic HCT","otherNames":["Allogeneic hematopoietic cell transplantation"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Morphologically confirmed acute myeloid leukemia (AML) (greater than 20% blasts in the peripheral blood or marrow) meeting any of the following criteria:\n\n  * Recurrent cytogenetic translocations\n\n    * t(8;21)(q22;q22)\n    * Bone marrow eosinophil abnormalities\n\n      * inv(16)(p13;q22)\n      * t(16;16)(p13;q22)\n    * 11q23 abnormalities\n  * Multilineage dysplasia without presence of myelodysplastic syndromes (MDS)\n  * Minimally differentiated AML\n  * AML without maturation\n  * AML with maturation\n  * AML not otherwise categorized\n  * Acute myelomonocytic leukemia\n  * Acute monocytic leukemia\n  * Acute erythroid leukemia\n  * Acute megakaryocytic leukemia\n  * Acute basophilic leukemia\n* Patients undergoing allogeneic transplantation must have a sibling donor match defined as human leukocyte antigen (HLA) match or haplotype match with one locus mismatch on other haplotype\n* Age 16 to 60\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-4\n* Aspartate aminotransferase (AST) less than 4 times upper limit of normal (ULN)\n* Alkaline phosphatase less than 4 times ULN\n* Creatinine no greater than 2.0 mg/dL\n* Creatinine clearance at least 50 mL/min\n* Left ventricular ejection fraction (LVEF) at least 45% by post-induction multigated acquisition (MUGA) scan\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* HIV negative\n* Prior hydroxyurea allowed\n* Prior corticosteroids allowed\n\nExclusion Criteria:\n\n* Recurrent cytogenetic translocations\n\n  * Acute promyelocytic leukemia (PML) with t(15;17)(q22;q21)\n  * Variant acute PML with t(v;17)\n* Multilineage dysplasia with prior MDS\n* Acute panmyelosis with myelofibrosis\n\n  * Blastic transformation of chronic myelogenous leukemia\n  * Secondary AML (chemotherapy-induced or evolved from MDS)\n  * Pregnant or nursing\n  * Bilirubin greater than 2.0 mg/dL (unless related to Gilbert's syndrome or hemolysis)\n  * Significant cardiac disease requiring active therapy (e.g., digoxin, diuretics, antiarrhythmics, or antianginal medications)\n  * Prior biologic therapy\n  * Prior cytotoxic chemotherapy for any malignancy\n  * Prior radiotherapy for any malignancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"60 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (Induction Phase)","description":"Overall survival is defined as the time from randomization in the induction phase to death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"23.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Disease-free Survival (Consolidation Phase)","description":"Disease-free survival is defined from the time of the confirmation of a complete remission via biopsy to the relapse of the disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"13.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Consolidation Phase)","description":"Overall survival is defined as the time from randomization in the consolidation phase to death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"27.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":328,"n":328},"commonTop":["Anemia","Thrombocytopenia","Leukopenia","Neutropenia","Nausea"]}}}